Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEMD NASDAQ:BTCY NASDAQ:LYRA NASDAQ:OSRH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEMDAethlon Medical$1.59-27.4%$1.34$1.08▼$8.44$5.69M1.727.71 million shs3.80 million shsBTCYBiotricity$0.53+10.4%$0.44$0.19▼$0.83$13.20M1.1238,264 shs9,323 shsLYRALyra Therapeutics$7.33-0.1%$8.53$3.81▼$37.50$12.07M0.1622,107 shs2,830 shsOSRHOSR$0.52+9.1%$1.01$0.45▼$13.40$10.19M1.49636,340 shs27.20 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEMDAethlon Medical-27.40%+39.47%+13.57%-50.05%-64.79%BTCYBiotricity+10.42%-15.93%+6.21%+3.92%+26.79%LYRALyra Therapeutics-0.12%+3.99%-12.62%+59.72%-56.22%OSRHOSR+9.57%-2.74%-49.51%-55.60%+51,499,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEMDAethlon Medical2.6873 of 5 stars3.05.00.00.03.00.00.6BTCYBiotricityN/AN/AN/AN/AN/AN/AN/AN/ALYRALyra Therapeutics3.2565 of 5 stars3.05.00.00.02.82.50.6OSRHOSRN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEMDAethlon Medical 2.00Hold$56.003,422.01% UpsideBTCYBiotricity 2.00HoldN/AN/ALYRALyra Therapeutics 2.00Hold$100.001,264.07% UpsideOSRHOSR 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest AEMD, BTCY, OSRH, and LYRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025AEMDAethlon MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral8/14/2025LYRALyra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral7/7/2025AEMDAethlon MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEMDAethlon Medical$570K7.25N/AN/A$1.32 per share1.20BTCYBiotricity$12.06M1.09N/AN/A($1.30) per share-0.41LYRALyra Therapeutics$770K15.66N/AN/A$0.99 per share7.41OSRHOSRN/AN/AN/AN/A$6.45 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEMDAethlon Medical-$13.39M-$12.64N/AN/AN/AN/A-266.21%-179.46%N/ABTCYBiotricity-$14.09M-$0.21N/A∞N/A-80.42%N/A-188.47%N/ALYRALyra Therapeutics-$93.43M-$29.01N/AN/AN/A-5,043.64%-404.56%-60.06%11/11/2025 (Estimated)OSRHOSR-$2.41MN/A0.00∞N/AN/A-12.19%-8.18%N/ALatest AEMD, BTCY, OSRH, and LYRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025OSRHOSRN/A$0.02N/A$0.02N/A$1.14 million8/13/2025Q1 2026AEMDAethlon Medical-$0.68-$0.85-$0.17-$0.85N/AN/A8/12/2025Q2 2025LYRALyra Therapeutics-$5.79-$5.51+$0.28-$5.51$0.18 million$0.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEMDAethlon MedicalN/AN/AN/AN/AN/ABTCYBiotricityN/AN/AN/AN/AN/ALYRALyra TherapeuticsN/AN/AN/AN/AN/AOSRHOSRN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEMDAethlon MedicalN/A2.492.49BTCYBiotricityN/A0.230.10LYRALyra TherapeuticsN/A2.782.78OSRHOSRN/A0.180.20Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEMDAethlon Medical1.99%BTCYBiotricity3.89%LYRALyra Therapeutics95.62%OSRHOSR55.30%Insider OwnershipCompanyInsider OwnershipAEMDAethlon Medical1.20%BTCYBiotricity10.10%LYRALyra Therapeutics3.25%OSRHOSR33.67%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEMDAethlon Medical102.60 million2.57 millionNo DataBTCYBiotricity4024.91 million22.08 millionOptionableLYRALyra Therapeutics501.65 million1.59 millionOptionableOSRHOSRN/A21.58 million14.32 millionN/AAEMD, BTCY, OSRH, and LYRA HeadlinesRecent News About These CompaniesOSR Holdings Amends Note Purchase AgreementAugust 20 at 5:51 PM | tipranks.comLatest OSR Holdings Stock News | NASDAQ:OSRH | BenzingaAugust 9, 2025 | benzinga.comOSR Holdings to Host Virtual Investor Event Providing Key Corporate Updates and Strategic Direction on August 6, 2025August 1, 2025 | prnewswire.comOSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share ...August 1, 2025 | morningstar.comMOSR Holdings Inc.: OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange StructureAugust 1, 2025 | finanznachrichten.deOSR Holdings Reveals Update on Woori IO Deal and Share ExchangeAugust 1, 2025 | msn.comOSR Holdings Provides Transparency Update on Equity Financing InstrumentsJuly 31, 2025 | prnewswire.comOSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange StructureJuly 30, 2025 | prnewswire.comOSR Holdings to acquire South Korea’s medical device company Woori IOJuly 28, 2025 | finance.yahoo.comOSR Holdings enters term sheet to acquire Woori IO (OSRH:NASDAQ)July 25, 2025 | seekingalpha.comOSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in ...July 25, 2025 | seekingalpha.comOSR Holdings signs term sheet to acquire noninvasive glucose tech firmJuly 25, 2025 | investing.comOSR Holdings signs term sheet to acquire South Korea-based noninvasive glucose monitoring technology company, Woori IOJuly 25, 2025 | pharmabiz.comPOSR Holdings enters term sheet to acquire Woori IOJuly 24, 2025 | msn.comOSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring TechnologyJuly 24, 2025 | prnewswire.comOSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR CompanyJuly 15, 2025 | prnewswire.comOSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D ...July 11, 2025 | taiwannews.com.twTOSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D Framework in Partnership with BCM Europe AG | MorningstarJuly 9, 2025 | morningstar.comMOSR Holdings plans $50 million security token offering in 2025July 9, 2025 | uk.investing.comOSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D Framework in Partnership with BCM Europe AGJuly 9, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAEMD, BTCY, OSRH, and LYRA Company DescriptionsAethlon Medical NASDAQ:AEMD$1.59 -0.60 (-27.40%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.59 0.00 (0.00%) As of 08/22/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation. The company was incorporated in 1999 and is based in San Diego, California.Biotricity NASDAQ:BTCY$0.53 +0.05 (+10.42%) As of 08/22/2025 03:51 PM EasternBiotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.Lyra Therapeutics NASDAQ:LYRA$7.33 -0.01 (-0.12%) Closing price 08/22/2025 03:57 PM EasternExtended Trading$7.18 -0.15 (-2.06%) As of 08/22/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.OSR NASDAQ:OSRH$0.52 +0.04 (+9.09%) As of 08/22/2025 03:59 PM EasternOSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot 3 Reasons Salesforce Is a Bargain Right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.